Gastrointestinal Stromal Tumor (GIST)

Adult trials (Ages 18 and older)

Interventional trials

All Mutation Types (KIT, PDGFRA D842V, Wild)

2nd Line Only

IRB #19262
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib (INTRIGUE)

3rd or 4th Line

IRB #18437
Phase 3 Study of BLU-285 versus Regorafenib in Patients with GIST and other Relapsed and Refractory Solid Tumors

IRB #20010
Early Access Program (EAP) for avapritinib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

4th Line

IRB #17155
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

PDGFRA D842V Only

At least 1 prior therapy

IRB #20010
Early Access Program (EAP) for avapritinib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

IRB #16365
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene

Any Line

CROSS-DISEASE TRIALS:

IRB# 19992
EAY131 (MATCH)

IRB# S1609
(DART)

http://www.ohsu.edu/research/rda/so/knight.php

Key

- Open for Enrollment
- In Development
- Enrollment on Hold

08/21/19